The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of BELLUS Health Inc. (“BELLUS” or “the Company”) (NASDAQ: BLU) for violations of the securities laws.

The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. BELLUS announced the topline results of its Phase 2 RELIEF trial for BLU-5937 on July 6, 2020. The Company’s trial failed to reach its primary endpoint of a statistically significant reduction in awake coughs per hour at various time points in the four doses tested. In fact, the Company’s drug candidate failed to outperform a placebo. Based on this news, shares of BELLUS fell by 70% on the same day.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200709005925/en/